Pricing & Access· August 8, 2026 · 14 min read
Novo Nordisk portfolio dossier (Q2 2026): Wegovy, CagriSema & obesity pipeline
By Ran Chen#Novo Nordisk#Semaglutide#Wegovy
Topic
Ozempic
Ozempic (semaglutide) type 2 diabetes coverage, gross-to-net pricing pressure, IRA negotiation exposure, and generic patent challenge filings.